DexCom, Inc.

$ 72.47 1.74 %

DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.

CEO: Jacob Steven Leach - https://www.dexcom.com

Price objectif

$83.56 15.30 %

Recommandation

Buy

DCF

$ 46.86

Loading data...

DXCM vs S&P500

Loading data...

No data available.

Quick ratio

1.64

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

31.10

is considered reasonable, suggesting that the company has a valuation in line with its current profits.

EPS

2.33

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

33.83 %

is generally considered excellent, indicating that the company is generating strong profits with its equity.

ROIC

18.03 %

generates a return higher than the cost of its capital, thereby creating value for its investors.

WACC

10.70

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.47

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

3.71

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

0.00 %

the dividend payout ratio is the measure of dividends paid out to shareholders relative to the company's net income.

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
8 indicates good financial health
Altman score
6.83 indicates good financial health and low risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
0.50 indicates that the company has a moderate ability to cover its short-term debts with its cash
Debt Ratio
0.21 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.